Table 4.
Prognostic factors for relapse-free survival in endometrioid endometrial cancers (n = 103): Multivariate Cox proportional-hazards regression model analysis
| HR | 95% CI | P-value | ||
|---|---|---|---|---|
| Stage | 0.566 | 0.065 | 4.958 | 0.607 |
| Grade | 38.285 | 1.882 | 778.700 | 0.018* |
| Invasion | 1.650 | 0.146 | 18.637 | 0.686 |
| LVSI | 6.567 | 1.087 | 39.676 | 0.040* |
| p-mTOR (nucleus) | 2.220 | 0.445 | 11.071 | 0.331 |
| p-mTOR (cytoplasma) | 1.592 | 0.346 | 7.323 | 0.550 |
| p-Ser167-ERα (nuclear) | 6.707 | 0.419 | 107.406 | 0.179 |
| p-Ser167-ERα (cytoplasma) | 1.464 | 0.105 | 20.386 | 0.777 |
| p-S6K1 | 0.265 | 0.037 | 1.905 | 0.187 |
| p-MAPK | 1.142 | 0.180 | 7.249 | 0.888 |
| p-p90RSK | 5.882 | 0.553 | 62.595 | 0.142 |
*
P < 0.05. CI, confidence interval; HR, hazards ratio; LVSI, lymphovascular space invasion; p-mTOR, phosphorylated mammalian target of rapamycin; p-p90RSK, phosphorylated p90 ribosomal S6 kinase; p-S6K1, phosphorylated p70 S6 kinase 1; p-Ser167-ERα, phosphorylated estrogen receptor α at Ser167.